The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
BACKGROUND: There are limitations to currently available biochemical tests for pheochromocytoma. Our objective was to evaluate the diagnostic efficacy of a novel tandem mass spectrometry assay for ...
If you buy something, we may earn an affiliate commission. If there’s one thing you don’t want to endure, it’s the symptoms of norovirus, a brutal stomach bug that tends to cause relentless ...
Primary focal hyperhidrosis has an average age of onset of 25 years; however, a large proportion of patients report having their symptoms for as long as they can remember. It would appear that ...